Ⅲ型前膠原羧基端原肽(PIIICP)多克隆抗體
Polyclonal Antibody to Procollagen III C-Terminal Propeptide (PIIICP)
P3CP; C-Propeptide Of Type III Procollagen; Procollagen III Carboxy Terminal Propeptide
- 編號(hào)UPAA963Ra02
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 來源多抗制備
- 宿主兔
- 效價(jià)-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 -
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度500μg/mL
- 且適物種-
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 360 ¥ 840 ¥ 1200 ¥ 3000 ¥ 12000
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
IHC圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)PIIICP的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別PIIICP。
用法
Western blotting: 0.5-2μg/mL
Immunohistochemistry: 5-20μg/mL
Immunocytochemistry: 5-20μg/mL
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA963Ra02 | Ⅲ型前膠原羧基端原肽(PIIICP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA963Ra01 | Ⅲ型前膠原羧基端原肽(PIIICP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA963Ra02 | Ⅲ型前膠原羧基端原肽(PIIICP)多克隆抗體 | WB; IHC; ICC; IP. |
| UCEA963Ra | Ⅲ型前膠原羧基端原肽(PIIICP)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA963Ra | Ⅲ型前膠原羧基端原肽(PIIICP)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Inflammation Research | Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy [pubmed:27516211] |
| Heart & Vessels | Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR [pubmed:28004175] |
| MOLECULAR MEDICINE REPORTS | Endothelial?to?mesenchymal transition in human idiopathic dilated cardiomyopathy [pubmed:29115553] |
| Heart and Vessels | Left ventricular reverse remodeling is not related to biopsy?detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR [10.1007/s00380-016-0930-y] |
| Cytokine | 12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis. [pubmed:28460256] |
| Advanced Healthcare Materials | Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events. [pubmed:29120858] |
| JOURNAL OF THROMBOSIS AND THROMBOLYSIS | Extracellular matrix collagen biomarkers levels in patients with chronic thromboembolic pulmonary hypertension [Pubmed: 33175289] |
留言咨詢
